Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1969 to 1977 of 1977 entries
Sorted by: Best Match Show Resources per page
A Fatal Extrapulmonary Manifestation of COVID-19.

Cureus

Harris CL, Achuthanandan S, Para K, Shetty V.
PMID: 33903831
Cureus. 2021 Mar 23;13(3):e14068. doi: 10.7759/cureus.14068.

Coronavirus disease 2019 (COVID-19) grew to pandemic proportions in 2020. Research has shown that the causative virus, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), uses the angiotensin-converting enzyme II (ACE-II) receptor to attack host cells. These ACE-II receptors...

Cite
Harris CL, Achuthanandan S, Para K, et al. A Fatal Extrapulmonary Manifestation of COVID-19. Cureus. 2021;13(3):e14068doi: 10.7759/cureus.14068.
Harris, C. L., Achuthanandan, S., Para, K., & Shetty, V. (2021). A Fatal Extrapulmonary Manifestation of COVID-19. Cureus, 13(3), e14068. https://doi.org/10.7759/cureus.14068
Harris, Chad L, et al. "A Fatal Extrapulmonary Manifestation of COVID-19." Cureus vol. 13,3 (2021): e14068. doi: https://doi.org/10.7759/cureus.14068
Harris CL, Achuthanandan S, Para K, Shetty V. A Fatal Extrapulmonary Manifestation of COVID-19. Cureus. 2021 Mar 23;13(3):e14068. doi: 10.7759/cureus.14068. PMID: 33903831; PMCID: PMC8062233.
Copy Download .nbib Format: NLM
Primary Versus Secondary NAFLD: Perspective on Advanced Fibrosis.

Journal of clinical and experimental hepatology

Shetty D, Amarapurkar A, Shukla A.
PMID: 34511816
J Clin Exp Hepatol. 2021 Sep-Oct;11(5):557-564. doi: 10.1016/j.jceh.2020.12.009. Epub 2020 Dec 31.

BACKGROUND: The presence of macrovesicular steatosis on liver biopsy is the commonest histopathological finding. Nonalcoholic fatty liver disease (NAFLD) is the presence of ≥5% macrovesicular steatosis without significant alcohol use. It is subdivided into primary and secondary NAFLD; information...

Cite
Shetty D, Amarapurkar A, Shukla A. Primary Versus Secondary NAFLD: Perspective on Advanced Fibrosis. J Clin Exp Hepatol. 2020;11(5):557-564doi: 10.1016/j.jceh.2020.12.009.
Shetty, D., Amarapurkar, A., & Shukla, A. (2021). Primary Versus Secondary NAFLD: Perspective on Advanced Fibrosis. Journal of clinical and experimental hepatology, 11(5), 557-564. https://doi.org/10.1016/j.jceh.2020.12.009
Shetty, Divya, et al. "Primary Versus Secondary NAFLD: Perspective on Advanced Fibrosis." Journal of clinical and experimental hepatology vol. 11,5 (2021): 557-564. doi: https://doi.org/10.1016/j.jceh.2020.12.009
Shetty D, Amarapurkar A, Shukla A. Primary Versus Secondary NAFLD: Perspective on Advanced Fibrosis. J Clin Exp Hepatol. 2021 Sep-Oct;11(5):557-564. doi: 10.1016/j.jceh.2020.12.009. Epub 2020 Dec 31. PMID: 34511816; PMCID: PMC8414329.
Copy Download .nbib Format: NLM
Clinical characteristics, laboratory parameters and outcomes of COVID-19 in cancer and non-cancer patients from a tertiary Cancer Centre in India.

Cancer medicine

Mirgh SP, Gokarn A, Rajendra A, More A, Kamtalwar S, Katti KS, Singh A, Goli VB, Ravind R, Madala R, Kakoti S, Maitre P, Punatar S, Chichra A, Patil A, Trivedi B, Joshi A, Patkar N, Tembhare P, Khanka T, Rajpal S, Chatterjee G, Kannan S, Subramanian PG, Murthy V, Shetty N, Chavan P, Bhat V, Nair S, Khattry N, Gupta S.
PMID: 34786866
Cancer Med. 2021 Dec;10(24):8777-8788. doi: 10.1002/cam4.4379. Epub 2021 Nov 16.

BACKGROUND: There is paucity of data regarding clinical characteristics, laboratory parameters and outcomes of coronavirus disease (COVID-19) in cancer versus non-cancer patients, particularly from India.MATERIALS AND METHODS: This was an observational, single-centre, retrospective analysis of patients with laboratory-confirmed COVID-19...

Cite
Mirgh SP, Gokarn A, Rajendra A, et al. Clinical characteristics, laboratory parameters and outcomes of COVID-19 in cancer and non-cancer patients from a tertiary Cancer Centre in India. Cancer Med. 2021;10(24):8777-8788doi: 10.1002/cam4.4379.
Mirgh, S. P., Gokarn, A., Rajendra, A., More, A., Kamtalwar, S., Katti, K. S., Singh, A., Goli, V. B., Ravind, R., Madala, R., Kakoti, S., Maitre, P., Punatar, S., Chichra, A., Patil, A., Trivedi, B., Joshi, A., Patkar, N., Tembhare, P., Khanka, T., Rajpal, S., Chatterjee, G., Kannan, S., Subramanian, P. G., Murthy, V., Shetty, N., Chavan, P., Bhat, V., Nair, S., Khattry, N., & Gupta, S. (2021). Clinical characteristics, laboratory parameters and outcomes of COVID-19 in cancer and non-cancer patients from a tertiary Cancer Centre in India. Cancer medicine, 10(24), 8777-8788. https://doi.org/10.1002/cam4.4379
Mirgh, Sumeet P, et al. "Clinical characteristics, laboratory parameters and outcomes of COVID-19 in cancer and non-cancer patients from a tertiary Cancer Centre in India." Cancer medicine vol. 10,24 (2021): 8777-8788. doi: https://doi.org/10.1002/cam4.4379
Mirgh SP, Gokarn A, Rajendra A, More A, Kamtalwar S, Katti KS, Singh A, Goli VB, Ravind R, Madala R, Kakoti S, Maitre P, Punatar S, Chichra A, Patil A, Trivedi B, Joshi A, Patkar N, Tembhare P, Khanka T, Rajpal S, Chatterjee G, Kannan S, Subramanian PG, Murthy V, Shetty N, Chavan P, Bhat V, Nair S, Khattry N, Gupta S. Clinical characteristics, laboratory parameters and outcomes of COVID-19 in cancer and non-cancer patients from a tertiary Cancer Centre in India. Cancer Med. 2021 Dec;10(24):8777-8788. doi: 10.1002/cam4.4379. Epub 2021 Nov 16. PMID: 34786866; PMCID: PMC8646792.
Copy Download .nbib Format: NLM
A Clinical Update on the Prognostic Effect of microRNA Biomarkers for Survival Outcome in Nasopharyngeal Carcinoma: A Systematic Review and Meta-Analysis.

Cancers

Shaw P, Senthilnathan R, Krishnan S, Suresh D, Shetty S, Muthukaliannan GK, Mani RR, Sivanandy P, Chandramoorthy HCK, Gupta MM, Baxi S, Jayaraj R.
PMID: 34503179
Cancers (Basel). 2021 Aug 29;13(17). doi: 10.3390/cancers13174369.

No abstract available.

Cite
Shaw P, Senthilnathan R, Krishnan S, et al. A Clinical Update on the Prognostic Effect of microRNA Biomarkers for Survival Outcome in Nasopharyngeal Carcinoma: A Systematic Review and Meta-Analysis. Cancers (Basel). 2021;13(17)doi: 10.3390/cancers13174369.
Shaw, P., Senthilnathan, R., Krishnan, S., Suresh, D., Shetty, S., Muthukaliannan, G. K., Mani, R. R., Sivanandy, P., Chandramoorthy, H. C. K., Gupta, M. M., Baxi, S., & Jayaraj, R. (2021). A Clinical Update on the Prognostic Effect of microRNA Biomarkers for Survival Outcome in Nasopharyngeal Carcinoma: A Systematic Review and Meta-Analysis. Cancers, 13(17), . https://doi.org/10.3390/cancers13174369
Shaw, Peter, et al. "A Clinical Update on the Prognostic Effect of microRNA Biomarkers for Survival Outcome in Nasopharyngeal Carcinoma: A Systematic Review and Meta-Analysis." Cancers vol. 13,17 (2021). doi: https://doi.org/10.3390/cancers13174369
Shaw P, Senthilnathan R, Krishnan S, Suresh D, Shetty S, Muthukaliannan GK, Mani RR, Sivanandy P, Chandramoorthy HCK, Gupta MM, Baxi S, Jayaraj R. A Clinical Update on the Prognostic Effect of microRNA Biomarkers for Survival Outcome in Nasopharyngeal Carcinoma: A Systematic Review and Meta-Analysis. Cancers (Basel). 2021 Aug 29;13(17). doi: 10.3390/cancers13174369. PMID: 34503179; PMCID: PMC8431423.
Copy Download .nbib Format: NLM
Modified bracket positioning holder.

Contemporary clinical dentistry

Raghuraj MB, Shetty N, Sharan.
PMID: 21957395
Contemp Clin Dent. 2011 Apr;2(2):142. doi: 10.4103/0976-237X.83070.

No abstract available.

Cite
Raghuraj MB, Shetty N, Sharan. Modified bracket positioning holder. Contemp Clin Dent. 2011;2(2):142doi: 10.4103/0976-237X.83070.
Raghuraj, M. B., Shetty, N., & Sharan. (2011). Modified bracket positioning holder. Contemporary clinical dentistry, 2(2), 142. https://doi.org/10.4103/0976-237X.83070
Raghuraj, M B, et al. "Modified bracket positioning holder." Contemporary clinical dentistry vol. 2,2 (2011): 142. doi: https://doi.org/10.4103/0976-237X.83070
Raghuraj MB, Shetty N, Sharan. Modified bracket positioning holder. Contemp Clin Dent. 2011 Apr;2(2):142. doi: 10.4103/0976-237X.83070. PMID: 21957395; PMCID: PMC3180840.
Copy Download .nbib Format: NLM
Prognostic value of lung shunt fraction in hepatocellular carcinoma and unresectable liver dominant metastatic colorectal cancer undergoing transarterial radioembolisation.

Nuclear medicine communications

Gosavi A, Puranik AD, Shah S, Agrawal A, Purandare NC, Shetty N, Gala K, Kulkarni S, Patkar S, Goel M, Shrikhande S, Ramaswamy A, Ostwal V, Rangarajan V.
PMID: 34887368
Nucl Med Commun. 2022 Jan 01;43(1):24-31. doi: 10.1097/MNM.0000000000001492.

AIM: To assess the overall survival and determine whether pre-TARE shunt fraction, tumor volume and tumor marker impact the outcome.METHODS: This is a retrospective study of 75 patients who were referred for 90Y-glass microsphere radioembolisation by a joint clinic...

Cite
Gosavi A, Puranik AD, Shah S, et al. Prognostic value of lung shunt fraction in hepatocellular carcinoma and unresectable liver dominant metastatic colorectal cancer undergoing transarterial radioembolisation. Nucl Med Commun. 2022;43(1):24-31doi: 10.1097/MNM.0000000000001492.
Gosavi, A., Puranik, A. D., Shah, S., Agrawal, A., Purandare, N. C., Shetty, N., Gala, K., Kulkarni, S., Patkar, S., Goel, M., Shrikhande, S., Ramaswamy, A., Ostwal, V., & Rangarajan, V. (2022). Prognostic value of lung shunt fraction in hepatocellular carcinoma and unresectable liver dominant metastatic colorectal cancer undergoing transarterial radioembolisation. Nuclear medicine communications, 43(1), 24-31. https://doi.org/10.1097/MNM.0000000000001492
Gosavi, Atul, et al. "Prognostic value of lung shunt fraction in hepatocellular carcinoma and unresectable liver dominant metastatic colorectal cancer undergoing transarterial radioembolisation." Nuclear medicine communications vol. 43,1 (2022): 24-31. doi: https://doi.org/10.1097/MNM.0000000000001492
Gosavi A, Puranik AD, Shah S, Agrawal A, Purandare NC, Shetty N, Gala K, Kulkarni S, Patkar S, Goel M, Shrikhande S, Ramaswamy A, Ostwal V, Rangarajan V. Prognostic value of lung shunt fraction in hepatocellular carcinoma and unresectable liver dominant metastatic colorectal cancer undergoing transarterial radioembolisation. Nucl Med Commun. 2022 Jan 01;43(1):24-31. doi: 10.1097/MNM.0000000000001492. PMID: 34887368.
Copy Download .nbib Format: NLM
Comparing psychotropic medication prescribing in personality disorder between general mental health and psychological services: retrospective cohort study.

BJPsych open

Kadra-Scalzo G, Garland J, Miller S, Chang CK, Fok M, Hayes RD, Moran P, Shetty H, Young AH, Stewart R.
PMID: 33762065
BJPsych Open. 2021 Mar 25;7(2):e72. doi: 10.1192/bjo.2021.34.

BACKGROUND: Although no drugs are licensed for the treatment of personality disorder, pharmacological treatment in clinical practice remains common.AIMS: This study aimed to estimate the prevalence of psychotropic drug use and associations with psychological service use among people with...

Cite
Kadra-Scalzo G, Garland J, Miller S, et al. Comparing psychotropic medication prescribing in personality disorder between general mental health and psychological services: retrospective cohort study. BJPsych Open. 2021;7(2):e72doi: 10.1192/bjo.2021.34.
Kadra-Scalzo, G., Garland, J., Miller, S., Chang, C. K., Fok, M., Hayes, R. D., Moran, P., Shetty, H., Young, A. H., & Stewart, R. (2021). Comparing psychotropic medication prescribing in personality disorder between general mental health and psychological services: retrospective cohort study. BJPsych open, 7(2), e72. https://doi.org/10.1192/bjo.2021.34
Kadra-Scalzo, Giouliana, et al. "Comparing psychotropic medication prescribing in personality disorder between general mental health and psychological services: retrospective cohort study." BJPsych open vol. 7,2 (2021): e72. doi: https://doi.org/10.1192/bjo.2021.34
Kadra-Scalzo G, Garland J, Miller S, Chang CK, Fok M, Hayes RD, Moran P, Shetty H, Young AH, Stewart R. Comparing psychotropic medication prescribing in personality disorder between general mental health and psychological services: retrospective cohort study. BJPsych Open. 2021 Mar 25;7(2):e72. doi: 10.1192/bjo.2021.34. PMID: 33762065; PMCID: PMC8058890.
Copy Download .nbib Format: NLM
Retroperitoneal fibrosis masquerading as pelvi-ureteric junction obstruction - Laparoscopic management.

International journal of surgery case reports

Chawda V, Joshi A, Shetty P.
PMID: 34915441
Int J Surg Case Rep. 2021 Dec 03;90:106652. doi: 10.1016/j.ijscr.2021.106652. Epub 2021 Dec 03.

INTRODUCTION: Retroperitoneal fibrosis (RPF) is a rare fibro-inflammatory condition which is characterized by development of extensive fibrosis throughout the retroperitoneum. It is classically centred over the anterior surface of the fourth and fifth lumbar vertebrae. It results in entrapment...

Cite
Chawda V, Joshi A, Shetty P. Retroperitoneal fibrosis masquerading as pelvi-ureteric junction obstruction - Laparoscopic management. Int J Surg Case Rep. 2021;90:106652doi: 10.1016/j.ijscr.2021.106652.
Chawda, V., Joshi, A., & Shetty, P. (2021). Retroperitoneal fibrosis masquerading as pelvi-ureteric junction obstruction - Laparoscopic management. International journal of surgery case reports, 90106652. https://doi.org/10.1016/j.ijscr.2021.106652
Chawda, Vishal, et al. "Retroperitoneal fibrosis masquerading as pelvi-ureteric junction obstruction - Laparoscopic management." International journal of surgery case reports vol. 90 (2021): 106652. doi: https://doi.org/10.1016/j.ijscr.2021.106652
Chawda V, Joshi A, Shetty P. Retroperitoneal fibrosis masquerading as pelvi-ureteric junction obstruction - Laparoscopic management. Int J Surg Case Rep. 2021 Dec 03;90:106652. doi: 10.1016/j.ijscr.2021.106652. Epub 2021 Dec 03. PMID: 34915441; PMCID: PMC8683720.
Copy Download .nbib Format: NLM
Building a more diverse biomedical engineering workforce: Biomedical engineering at the university of the district of Columbia, a historically black college & university.

Thompson LA, Adebayo AS, Zhang N, Haghani S, Dowell K, Shetty D.
UIID-AD: 4309
2016;4325-4328. doi: 10.1109/EMBC.2016.7591684.

Biomedical Engineering (BME) is a new, multidisciplinary, and rapidly growing field, however, the BME Workforce suffers from limited ethnic and gender diversity. Despite the demand and growth of this new field due to its public health importance, only 4...

Cite
Thompson LA, Adebayo AS, Zhang N, et al. Building a more diverse biomedical engineering workforce: Biomedical engineering at the university of the district of Columbia, a historically black college & university. 2016;4325-4328doi: 10.1109/EMBC.2016.7591684.
Thompson, L. A., Adebayo, A. S., Zhang, N., Haghani, S., Dowell, K., & Shetty, D. (2016). Building a more diverse biomedical engineering workforce: Biomedical engineering at the university of the district of Columbia, a historically black college & university. 4325-4328. https://doi.org/10.1109/EMBC.2016.7591684
Thompson, L A, et al. "Building a more diverse biomedical engineering workforce: Biomedical engineering at the university of the district of Columbia, a historically black college & university." vol. (2016): 4325-4328. doi: https://doi.org/10.1109/EMBC.2016.7591684
Thompson LA, Adebayo AS, Zhang N, Haghani S, Dowell K, Shetty D. Building a more diverse biomedical engineering workforce: Biomedical engineering at the university of the district of Columbia, a historically black college & university. 2016;4325-4328. doi: 10.1109/EMBC.2016.7591684. UIID-AD: 4309.
Copy Download .nbib Format: NLM
Showing 1969 to 1977 of 1977 entries